BCMA-Targeted Therapy in Patients with Multiple Myeloma

home / case-based-roundtable-series / bcma-targeted-therapy-in-patients-with-multiple-myeloma

This roundtable series reviews the use of B-cell maturation antigen–targeted treatments in patients with relapsed/refractory multiple myeloma, as discussed by participants at virtual live events.

Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma

Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma

Targeted Oncology Staff
January 26th 2022

During a live virtual event, Natalie Callander, MD, discussed possible treatment options for a patient who relapsed several years after successful treatment of multiple myeloma with bortezomib, lenalidomide, and dexamethasone.

Part 2: Choosing Between BCMA and CAR T-Cell Therapy in Multiple Myeloma

Part 2: Choosing Between BCMA and CAR T-Cell Therapy in Multiple Myeloma

Targeted Oncology Staff
February 4th 2022

During a live virtual event, Natalie Callander, MD, discussed real-world experience with the efficacy of belantamab mafodotin and whether it can be chosen instead of chimeric antigen receptor T-cell therapy.

Part 1: Reviewing Late-Line Options for Relapsed/Refractory Multiple Myeloma

Part 1: Reviewing Late-Line Options for Relapsed/Refractory Multiple Myeloma

Targeted Oncology Staff
March 30th 2022

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.